Clinical trial NCT02986438: Treatment With Transcranial Magnetic Stimulation for Cocaine Addiction: Clinical Response and Functional Connectivity.
Official title: Effects of Transcranial Magnetic Stimulation on Functional Connectivity and Response to Treatment of Cocaine Dependent Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cocaine-Related Disorders
Keywords: Cocaine
Addiction
rTMS
fMRI
Lead sponsor: Instituto Nacional de Psiquiatría Dr. Ramón de la Fuente
Sponsor class: OTHER
Collaborators: name: National Council of Science and Technology, Mexico
First posted: 2016-12-08
Enrollment: 40
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Double-blind randomized control trial
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to investigate the short and long term clinical and cognitive effects of repetitive Transcranial Magnetic Stimulation (rTMS) at 5 Hz and/or 10 Hz frequencies on the left dorsolateral prefrontal cortex in cocaine dependent patients and to examine possible changes in brain structure and functional connectivity associated with this intervention.

Detailed description: Repetitive transcranial magnetic stimulation (rTMS) has been shown to reduce craving in cocaine addicts in the short term. However, there are no studies on the long term clinical and cognitive effects of sustained rTMS therapy. Moreover, clinical improvement or decline could be related to long term changes in brain structure and function. The purpose of this study is to investigate the short and long term clinical and cognitive effects of repetitive Transcranial Magnetic Stimulation (rTMS) at 5 Hz and/or 10 Hz frequencies on the left dorsolateral prefrontal cortex in cocaine dependent patients and to examine possible changes in brain structure and functional connectivity associated with this intervention. For this purpose the investigators will recruit cocaine dependent patients and stimulate them using rTMS with a acute intervention (twice a day for 2 weeks) and a maintenance intervention (twice a week for 3 months). The investigators will follow the patients to determine clinical outcome. The investigators will also measure clinical, cognitive and brain structural and functional connectivity to asses changes related to the intervention in the short and long term (measurements at: baseline, 2 weeks and 3 months).

Procedure:

The projects consists of: Screening Visit, Part 1 and Part 2.

First, there will be a screening visit, where a clinical interview will be conducted and tests will be applied to select study participants who meet the inclusion and exclusion criteria.

Baseline clinical, cognitive and neuroimaging data will be acquired. The cognitive and neuroimaging data will be exploratory, to be associated with the outcome measures. Part 1 of the study entails the determination of the rTMS target frequency (5 or 10 Hz) for Part 2 (long term stimulation). In Part 1, all participants will be randomly assigned to one of the four treatment legs with rTMS (10Hz, 10Hz-Sham, 5Hz, 5Hz-Sham). Participants will receive 20 sessions of rTMS (intervention or sham), twice per day for 10 consecutive days. Each session lasts approximately 35 minutes.

At 2 weeks, the investigators will evaluate the short term effect of treatment by measuring clinical, cognitive and neuroimaging changes and select which frequency of stimulation is the most effective in terms of clinical improvement, but also in terms of the rate of secondary effects. Our hypothesis is that 5 Hz is as effective as 10 Hz without the high rate of secondary effects (i.e. seizures).

In Part 2 of the study, the sham groups will end and they will be invited to the treatment condition although they data not will be considered for later phases. Here the maintenance phase starts (long term), where rTMS will be performed twice a week for 12 months using the target frequency (5 or 10 Hz). Clinical, cognitive and neuroimaging data will be acquired at 2 weeks and 3 months.

Eligibility criteria: Inclusion Criteria:

* Minimum age of eighteen and maximum of fifty years.
* Cocaine users for at least 1 year, currently using at least 3 times a week, with abstinence periods continuing to be less than one month in the last year.
* The reading level of at least 6th grade of primary (equivalent to fifth grade of elementary school).
* The ability to give a valid informed consent.
* Right-handed (in order to control by cerebral laterality in Neuroimaging).
* If the subject is female and of childbearing age, she agrees to use a medically acceptable form of contraception, and to not become pregnant during the duration of the study. A woman is considered to have potential for pregnancy, unless she is postmenopause or surgically sterilized. Female patients of childbearing potential should use either: (1) contraceptive pill or hormone preparation IUD or deposit (ring, injection, implant); And / or (2) a barrier method of contraception, such as the diaphragm, spermicide sponge, or a condom.

Contraceptive measures will be reviewed with the female subjects at each visit prior to the rTMS treatment.

* Self-report of experiencing cocaine craving when exposed to cocaine-associated cues.
* Body mass index less or equal to 30, allowing them to safely enter the Magnetic Resonance.

Exclusion Criteria:

* Personal or first-degree family history of any clinically defined neurological disorder, including organic brain disease, epilepsy, brain events, brain injury, or multiple sclerosis; Or personal history of previous neurosurgery or traumatic brain injury that have produced loss of consciousness.
* Cardiac pacemakers, neural stimulators, implantable defibrillators, implanted medication pumps, intracardiac lines, or acute, unstable heart disease, with intracranial implants (eg, aneurysm clips, leads, stimulators, cochlear implants, or electrodes) or with any other Metallic object inside or near the head that can not be safely removed.
* Screw metal or metallic projectiles into the head or body.
* Current use of any investigational drug or any anti-proconvulsant drug such as tricyclic or neuroleptic antidepressants (which reduce the seizure threshold).
* Increased intracranial pressure (decreasing seizure threshold).
* History of schizophrenia, bipolar disorder, mania or hypomania.
* History of myocardial infarction, angina pectoris, congestive heart failure, cardiomyopathy, cerebrovascular events or transient ischemic attack, or any heart condition currently under medical care.
* Women with reproductive potential who do not use an acceptable form of contraception pregnant or who are lactating.
* Any history of seizures.
* The current dependence (DSM-V criteria) on substances other than cocaine and / or nicotine.
* Claustrophobia making them unable to tolerate lying inside the MRI scanner.
* History of HIV infection or HIV antibody test positive (Due to potential neuroinfection).

These data will be corroborated by a screening visit where the following instruments will be used:

Clinical Interview. Self-applicable demographic questionnaire. Mini International Neuropsychiatric Interview (MINI-Plus). Structured clinical interview for DSM Axis II, self report (SCID-II).

Elimination criteria:

The participation of all participants during the study will be suspended if:

* They express their desire to stop participating.
* They present abnormal radiological findings that require more attention outside the study to ensure the health of the participant.
* Worsening of clinical condition.

Primary outcomes:
measure: Change in Cocaine Craving (CCQ)
timeFrame: Baseline, 2 weeks, 3 months
measure: Change in Cocaine Craving (VAS)
timeFrame: Baseline, 2 weeks, 3 months
measure: Change in Cocaine Urine Test
timeFrame: Baseline, 2 weeks, 3 months
Secondary outcomes:
measure: Changes in Psychopathological Symptoms
timeFrame: Baseline, 2 weeks, 3 months
measure: Changes in Depression
timeFrame: Baseline, 2 weeks, 3 months
measure: Changes in Anxiety
timeFrame: Baseline, 2 weeks, 3 months
measure: Changes in Drug Consumption and Related Problems
timeFrame: Baseline, 2 weeks, 3 months
measure: Changes in Sleep Quality: PSQI
timeFrame: Baseline, 2 weeks, 3 months
measure: Changes in Impulsivity
timeFrame: Baseline, 2 weeks, 3 months
measure: Lapse rate
timeFrame: Baseline, 2 weeks, 3 months
measure: Relapse rate
timeFrame: Baseline, 2 weeks, 3 months
Other outcomes:
Locations:
city: Mexico City
country: Mexico
facility: Instituto Nacional de Psiquiatría "Ramón de la Fuente Muñiz"
Study officials:
affiliation: Universidad Nacional Autonoma de Mexico
name: Eduardo A Garza-Villarreal, MD, PHD
role: PRINCIPAL_INVESTIGATOR
affiliation: Instituto Nacional de Psiquiatria "Ramon de la Fuente Muñiz"
name: Ruth Alcala-Lozano, MD, MSc
role: PRINCIPAL_INVESTIGATOR
References:
citation: Garza-Villarreal EA, Alcala-Lozano R, Fernandez-Lozano S, Morelos-Santana E, Davalos A, Villicana V, Alcauter S, Castellanos FX, Gonzalez-Olvera JJ. Clinical and Functional Connectivity Outcomes of 5-Hz Repetitive Transcranial Magnetic Stimulation as an Add-on Treatment in Cocaine Use Disorder: A Double-Blind Randomized Controlled Trial. Biol Psychiatry Cogn Neurosci Neuroimaging. 2021 Jul;6(7):745-757. doi: 10.1016/j.bpsc.2021.01.003. Epub 2021 Jan 26.